NewTimeSpace News,TONGGUAN GOLD completed the partial conversion of convertible bonds on January 28 in accordance with the notice from the bondholder. It allotted 6 million new shares at a conversion price of HK$1.1 per share, corresponding to the converted bond principal of HK$6.6 million.
NewTimeSpace News, PROSP GP INTL announced that it has successfully completed the placement of 33.365 million new shares pursuant to the general mandate on January 28. The placement price is HK$0.34 per share, with net proceeds of approximately HK$10.54 million, which are intended to be fully used for the Group's general working capital.
NewTimeSpace News, ND PAPER issued a positive profit warning on January 28, expecting that for the six months ended December 31, 2025, the profit attributable to equity holders of the company will be between RMB 1.95 billion and RMB 2.05 billion, representing a substantial increase of 315.2% to 336.5% compared with the same period last year.
Seres was listed on the Hong Kong Stock Exchange on 5 November 2025 at an offer price of HK$131.50 per share; net proceeds were about HK$14.283 billion. The IPO brought in 22 cornerstone investors who subscribed a combined HK$6.421 billion. Since listing, the share price has remained below the offer price; as of 27 January 2026 the cumulative decline is roughly 25%. According to the company’s financial report, revenue for the first nine months of 2025 was RMB 110.534 billion and net profit rose 31.56% year-on-year. Revenue is highly dependent on the AITO brand, whose vehicle sales account for more than 90% of total turnover.
NewTimeSpace News: BEXCELLENT GP issued a positive profit forecast on January 27. For the four months ended November 30, 2025, the group's unaudited consolidated net profit attributable to owners of the company was approximately HK$3 million, turning around from a loss in the same period of the previous year.
NewTimeSpace News: The Stock Exchange of Hong Kong Limited (HKEX) announced on January 27 that it has imposed a reprimand and a declaration of unfitness to act as director against Mr. Yu Bin, former Executive Director and Chairman of Skyfame Realty (Holdings) Limited (00059.HK). The Exchange determined that Mr. Yu failed to fulfill his obligation to cooperate in investigations conducted by the Securities and Futures Commission (SFC) and HKEX’s Listing Division, in violation of the Listing Rules.
NewTimeSpace News: POLY PROPERTY issued a voluntary announcement on January 27, stating that its wholly-owned subsidiary Shanghai Poly Property successfully issued the second tranche of 2026 medium-term notes on January 22. The issuance scale is RMB500 million with a three-year term and a coupon rate of 2.95% per annum. The proceeds raised will be used to replace the own funds allocated for repaying debt financing instruments.
NewTimeSpace News: CHINA OIL & GAS announced the launch of a cash tender offer on January 27, aiming to repurchase its outstanding US$361 million 4.7% senior notes at a price of US$1,000 per US$1,000 principal amount.
AUX Electric listed on the Hong Kong Stock Exchange on September 2, 2025, at an offering price of HK$17.42 per share. Prior to listing, AUX Electric distributed approximately RMB 3.794 billion in dividends in 2024, representing 55.47% of combined net profit for the three-year period from 2022 to 2024. Following its debut below IPO price, the company remains in a post-IPO decline to this day. Since listing through January 26, 2026, AUX Electric has cumulatively declined 21.93% compared to its offering price.
InSilico Medicine has partnered with Qilu Pharmaceutical in a deal worth over HK$931 million to develop small molecule inhibitors for cardiovascular and metabolic diseases using its Pharma.AI platform, with milestone payments and single-digit sales royalties.
ANTA Sports announced its proposed acquisition of approximately 29.06% of PUMA from Artémis for EUR 1.505 billion (approximately RMB 12.28 billion), which would make it the largest shareholder. The transaction constitutes a major transaction subject to shareholder and regulatory approvals including anti-trust clearance and NDRC approval, with consideration to be funded from internal resources, aligning with the Company's "Single-Focus, Multi-Brand and Globalization" strategy, and the Group intends to seek representation on PUMA's Supervisory Board following completion.
NewTimeSpace News: SSY Group Limited (02005.HK) released a voluntary announcement on the 26th stating that it has obtained the drug production registration approval from the National Medical Products Administration of China (NMPA) for the new 2ml specification of Potassium Dihydrogen Phosphate Complex Injection. Classified as a Class 3 chemical drug, the product is deemed to have passed the consistency evaluation.
NewTimeSpace News, HENGRUI PHARMA announced on January 26 that it has received the "Drug Clinical Trial Approval Notice" for SHR-1049 Injection issued by the National Medical Products Administration (NMPA), which grants approval for the drug to conduct a single-agent clinical trial for the treatment of advanced solid tumors.
NewTimeSpace News , EMINENCE ENT announced the completion of a placement pursuant to general mandate on January 26. The company issued 115.88 million new shares to six independent third-party placees at HK$0.32 per share, raising a total of HK$37.0816 million. After deducting relevant costs, the net proceeds amount to approximately HK$36.7108 million, which are intended for the refinancing and repayment of existing bank loans.
NewTimeSpace News: Zhaoke Ophthalmology Limited (06622.HK) announced that it has expanded its collaboration agreement with AFT Pharmaceuticals and established a new strategic partnership with Japanese ophthalmology company Santen Pharmaceutical, to advance the commercialization of its core investigational presbyopia treatment drug BRIMOCHOL™ PF in Singapore and Vietnam respectively. The Prescription Drug User Fee Act (PDUFA) date for the drug’s New Drug Application (NDA) in the U.S. is set for January 28, 2026.
FIRST SERVICE announced a change in executive director on January 26. Mr. Jin Chungang resigned from the position due to a shift in work focus and was transferred to Group Deputy General Manager, responsible for the overall operation and management of the company in Northwest China. Mr. Wang Song was appointed as Executive Director with a three-year term.
